

High prevalence of PI resistance in patients failing second-line ART in Vietnam

Vu Phuong Thao¹, Vo Minh Quang², Jeremy N. Day^{1,3}, Nguyen Tran Chinh², Cecilia M. Shikuma⁴, Jeremy Farrar^{1,3}, Nguyen Van Vinh Chau², Guy E. Thwaites^{1,3}, Sarah J. Dunstan⁵ and Thuy Le^{1,3,4*}

¹Wellcome Trust Major Overseas Programme, Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam; ²Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam; ³Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK; ⁴Hawaii Center for AIDS, University of Hawaii at Manoa, Honolulu, HI, USA; ⁵The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, Victoria, Australia

*Corresponding author. Oxford University Clinical Research Unit, Hospital for Tropical Diseases, 764 Vo Van Kiet, District 5, Ho Chi Minh City, Vietnam. Tel: +84-8-3838-4010; Fax: +84-8-3923-8904; E-mail: thuy@oucru.org

Received 13 July 2015; returned 21 August 2015; revised 12 October 2015; accepted 16 October 2015

Background: There are limited data from resource-limited settings on antiretroviral resistance mutations that develop in patients failing second-line PI ART.

Methods: We performed a cross-sectional virological assessment of adults on second-line ART for ≥ 6 months between November 2006 and December 2011, followed by a prospective follow-up over 2 years of patients with virological failure (VF) at the Hospital for Tropical Diseases, Vietnam. VF was defined as HIV RNA concentrations ≥ 1000 copies/mL. Resistance mutations were identified by population sequencing of the *pol* gene and interpreted using the 2014 IAS-USA mutation list and the Stanford algorithm. Logistic regression modelling was performed to identify predictors of VF.

Results: Two hundred and thirty-one patients were enrolled in the study. The median age was 32 years; 81.0% were male, 95.7% were on a lopinavir/ritonavir-containing regimen and 22 (9.5%) patients had VF. Of the patients with VF, 14 (64%) carried at least one major protease mutation [median: 2 (IQR: 1–3)]; 13 (59%) had multiple protease mutations conferring intermediate- to high-level resistance to lopinavir/ritonavir. Mutations conferring cross-resistance to etravirine, rilpivirine, tipranavir and darunavir were identified in 55%, 55%, 45% and 27% of patients, respectively. Higher viral load, adherence $< 95\%$ and previous indinavir use were independent predictors of VF. The 2 year outcomes of the patients maintained on lopinavir/ritonavir included: death, 7 (35%); worsening virological/immunological control, 6 (30%); and virological re-suppression, 5 (25%). Two patients were switched to raltegravir and darunavir/ritonavir with good HIV control.

Conclusions: High-prevalence PI resistance was associated with previous indinavir exposure. Darunavir plus an integrase inhibitor and lamivudine might be a promising third-line regimen in Vietnam.

Introduction

The WHO endorses ritonavir-boosted PI (PIr)-based ART as an efficacious second-line treatment after failure of NNRTI-based first-line therapy in resource-limited settings.¹ PIr-based therapy is highly potent in ART-naïve patients participating in clinical trials^{2–4} and has a high efficacy as a second-line therapy in resource-limited settings.^{5,6} Nevertheless, $\leq 20\%$ of patients in resource-rich and 27% of patients in resource-limited settings develop virological failure (VF) on PIr-based ART.^{4,6,7} PI resistance is rarely observed in patients failing PIr-based therapy in clinical

trials^{3,4,8,9} and, similarly, is uncommon (range: 0%–7%) in PI-naïve patients failing second-line therapy in sub-Saharan Africa.^{10–14} However, studies from Cambodia¹⁵ and India¹⁶ have reported PI-resistance-mutation prevalences of 40% and 70% in patients failing second-line ART, respectively. There are few data regarding the prevalence of and risk factors for PI resistance developed on second-line ART in Asia. Significant uncertainty exists regarding the risk factors for PI resistance in programmatic settings, the contribution of HIV-1 subtypes to mutation development and the clinical outcomes in patients with PI resistance on long-term second-line ART. HIV-1 subtype CRF01_AE accounts for

99% of HIV infections in Vietnam,^{17–21} which is among the Asian countries with the highest numbers of HIV infections.^{22,23} Of the 90 000 people on ART, 3% are on second-line therapy.²³ Because of its costs, viral load monitoring of HIV is not performed routinely. Therefore, data on virological outcome and drug resistance in patients on second-line therapy are lacking. To this end, we aimed to generate data on antiretroviral resistance profiles of HIV-1 CRF01_AE-infected patients with viraemia on second-line PI therapy at the largest HIV treatment centre in Vietnam. Our objectives were: (i) to identify the risk factors for resistance development; (ii) to describe the long-term clinical outcomes of patients with resistance maintained on a failing second-line regimen; and (iii) to investigate cross-resistance to second-generation NNRTIs and PIs to inform national policy on third-line therapy.

Methods

Study setting and design

The study was conducted at the Hospital for Tropical Diseases (HTD) in Ho Chi Minh City (HCMC). The HTD is the largest centre for HIV care in southern Vietnam, providing ART for more than 5000 patients according to the national ART programme. Until the de-centralization of care in 2011–12, the HTD had been the primary provider of second-line ART for patients living in the 17 southern provinces of Vietnam. First-line therapy was administered according to national and international guidelines and at the time of the study consisted of two NRTIs (lamivudine in combination with either zidovudine or stavudine) and one NNRTI—either nevirapine or efavirenz. Indinavir was generically and locally produced (STADA, Vietnam) during this time and was prescribed (without ritonavir boosting) in public and private settings for patients with treatment failure or intolerance on nevirapine before efavirenz became available in 2004.²⁴ In 2011, tenofovir disoproxil fumarate replaced stavudine as a preferred NRTI backbone drug. Patients in the national programme were required to attend monthly appointments for clinical and adherence evaluation. CD4 cell count was performed every 6 months. HIV load testing was performed to confirm treatment failure when the WHO's defined clinical and/or immunological failure criteria were met.^{25,26} HIV genotyping was performed to diagnose antiretroviral resistance prior to therapy switch, and results were reported to treating clinicians. Second-line therapy included nelfinavir prior to 2006 and lopinavir/ritonavir thereafter, in combination with tenofovir disoproxil fumarate and/or zidovudine plus lamivudine.^{27,28}

This study consisted of a cross-sectional survey of adult patients (age ≥ 15 years) who had been on second-line ART for at least 6 months and were on active care to identify those with VF and their drug resistance development, followed by a prospective follow-up over 2 years of patients with VF. VF was defined as at least two viral loads ≥ 1000 copies/mL measured 1–3 months apart after intensive adherence counselling. The patients who had been on second-line therapy for < 6 months at the time of study assessment, who died or who switched therapy due to drug intolerance were excluded. The study was conducted between December 2011 and June 2014.

Data collection

Clinical data, including demographic information, HIV risk factors, ART history, CD4 counts, HIV viral load, genotyping results at the time of therapy switch (if available), AIDS events and therapy adherence, were obtained both retrospectively and prospectively from patients' charts and from one-on-one interviews.

ART adherence evaluation

Treating clinicians routinely assessed adherence according to the national guidelines at all clinic visits; adherence was recorded either as an

estimated percentage of pills taken or as a qualitative assessment of 'good', 'average' or 'poor', corresponding to $\geq 95\%$, 80%–94% or $< 80\%$ adherence, respectively.²⁶ Additionally, for this study, adherence was evaluated over the 6 months preceding the time of study assessment using a simple self-reported visual analogue scale (VAS).²⁹ For analysis, sub-optimal adherence was defined as having at least one adherence score of $< 95\%$ by pill count or by the VAS and/or receiving at least one qualitative adherence assessment of 'average' or 'poor' over the preceding 6 months prior.

HIV RNA measurement and antiretroviral resistance testing

At the time of enrolment, 5 mL of EDTA blood was collected for viral load measurement using the Abbott m2000rt Real Time HIV-1 assay (limit of detection of 150 copies/mL) (Abbott Laboratories, Abbott Park, IL, USA). Antiretroviral resistance testing was performed for patients with VF using an in-house population sequencing and sequence analysis protocol as previously described, with bidirectional coverage of the complete protease gene and reverse transcriptase codons 10–300.¹⁸ The sequences were analysed using SeqScape (Applied Biosystems). Nucleotide changes were determined by comparison with the consensus sequence pNL4-3 for HIV-1 subtype B (GenBank accession number M19921). Antiretroviral resistance mutations were identified based on the 2014 IAS-USA mutation list.³⁰ The antiretroviral resistance profile of each patient was predicted using the Stanford resistance interpretation algorithm (<http://hivdb.stanford.edu>). The Rega HIV-1 subtyping tool was used to determine the HIV-1 subtype of each patient sample.³¹

Statistical analyses of predictors of VF

The following pre-defined covariates were included in the logistic regression model: CD4 cell count and (\log_{10} -transformed) HIV RNA load at therapy switch, history of indinavir use, second-line therapy delay (defined as time in months from first detection of failure of first-line ART to time of second-line therapy initiation) and an overall measure of therapy adherence ($< 95\%$ versus $\geq 95\%$). The chosen covariates were either established risk factors for ART outcome^{5,32–36} or were based on clinicians' observations (i.e. previous indinavir use). Both univariate and multivariable analyses were performed.

Follow-up of patients with VF

The results of viral load and resistance testing were reported to the treating clinicians. Patients with VF then received intensive adherence counselling. As third-line therapy was not available through the national programme, these patients were continued on the current treatment according to national guidelines. The clinical and immunological outcomes of these patients over the following 24 months were evaluated. HIV RNA load was re-tested at month 24, and repeat genotype testing was performed if HIV RNA concentrations were ≥ 1000 copies/mL, to evaluate the evolution of resistance mutations in these patients.

Ethics

The study was approved by the scientific and ethics committee of the HTD. All patients gave written consent prior to study enrolment.

Results

Study population and characteristics

Figure 1 describes the study participants, virological outcome and follow-up of the patients with VF maintained on the failing




Figure 1. Flow chart of the study participants, virological outcome and follow-up of patients with VF maintained on the failing second-line ART. *24 months follow-up. DRVr, ritonavir-boosted darunavir; RAL, raltegravir; 3TC, lamivudine.

second-line regimen. Of 373 patients who started second-line ART between November 2006 and December 2011, 44 (11.8%) had died, 2 had been lost to follow-up and 51 (13.7%) had been transferred to other provincial clinics by the time of the study. Forty-one (11.0%) patients who had been on second-line ART for <6 months and four patients who switched therapy due to first-line therapy intolerance were excluded. The remaining 231 patients were enrolled into the study. Table 1 shows the characteristics of the 231 patients. The median age was 32 years; 81% were men. The median CD4 cell count and HIV RNA concentration at the time of therapy switch were 44 cells/mm³ and 5.1 log₁₀ copies/mL, respectively. The median time on second-line ART was 29 months (IQR: 16–43 months). Nelfinavir was the starting PI in 10 (4.3%) patients, but it was replaced by lopinavir/ritonavir within 12 months for all patients. A total of 36 (17.1%) patients had a history of treatment with indinavir, which was frequently prescribed at 800 mg twice daily or 400 mg three times daily. Sub-optimal adherence was identified in 12.1% patients.

Antiretroviral resistance mutations detected in patients prior to second-line therapy switch

Because of cost constraints, HIV genotyping was performed only for 173 of 231 (74.9%) patients prior to therapy switch. Figure 2 shows the mutations and prevalences detected in these patients.

Mutations conferring high-level resistance to NRTIs were detected in 168 of 173 (97.1%) patients, and to NNRTIs in 163 of 173 (94.2%) patients. High-level resistance to PIs was detected in 4 of 173 (2.3%) patients. Resistance mutations to both NRTIs and NNRTIs were present in 161 of 173 (93.1%) patients and to all three drug classes in 6 of 173 (3.5%) patients. The most common NRTI resistance mutations were M184I/V (86.1%), thymidine analogue mutations M41L, D67N, K70E/R, T215F/Y and K219E/Q (33%–57%), Q151M (22.5%) and K65R (16.2%). One hundred and forty-two (82.1%) patients harboured multiple thymidine analogue mutations and multiple NRTI resistance mutations (Q151M complex). Two patients had a T69 insertion mutation. The most common NNRTI resistance mutations were Y181C/I/V (48.6%), G190A/S (42.8%) and K103N (30.1%). At least three major NNRTI resistance mutations were present in 55 of 173 (31.8%) patients. Eight patients carried at least one major PI resistance mutation. The most common protease mutations were M46I/L (2.9%), L90M (1.7%) and V82A (1.2%).

Predicted resistance to second-line ART regimen

The predicted susceptibilities to the national second-line regimens containing tenofovir disoproxil fumarate, lamivudine and lopinavir/ritonavir were evaluated for the 173 patients who had genotype results using the Stanford HIV Drug Resistance algorithm.

Table 1. Characteristics of 231 patients on second-line ART in HCMC

Characteristic	
Male, <i>n</i> (%)	187 (81.0)
Age (years), median (IQR)	32 (28–36)
Previous history of injecting drug use, <i>n</i> (%); <i>N</i> =230	93 (40.4)
CD4 count (cells/mm ³), median (IQR); <i>N</i> =227	44 (17–84)
HIV RNA concentration (log ₁₀ copies/mL), median (IQR); <i>N</i> =215	5.1 (4.6–5.5)
Previous indinavir use, <i>n</i> (%); <i>N</i> =211	36 (17.1)
Time on second-line therapy (months), median (IQR)	29 (16–43)
Second-line regimens, <i>n</i> (%)	
initial regimens	
TDF/3TC/LPVR	112 (48.5)
TDF/3TC/LPVR+AZT	82 (35.5)
LPVR+other NRTIs ^a	27 (11.7)
NFV+other NRTIs ^a	10 (4.3)
regimens at time of study assessment	
TDF/3TC/LPVR	128 (55.4)
TDF/3TC/LPVR+AZT	88 (38.1)
LPVR+other NRTIs ^a	15 (6.5)
Adherence, <i>n</i> (%)	
≥95%	203 (87.9)
<95%	28 (12.1)

TDF, tenofovir disoproxil fumarate; 3TC, lamivudine; LPVR, lopinavir/ritonavir; AZT, zidovudine; NFV, nelfinavir.

^aOther NRTIs include two or three of the following drugs: abacavir, didanosine, zidovudine, lamivudine, stavudine or tenofovir disoproxil fumarate.

Intermediate- to high-level resistance to tenofovir disoproxil fumarate was present in 120 of 173 (69.4%), to lamivudine in 165 of 173 (95.4%) and to lopinavir/ritonavir in 2 of 173 (1.2%).

The numbers of patients predicted to receive one, two and three fully active drugs were 138 of 173 (79.8%), 25 of 173 (14.5%) and 4 of 173 (2.3%), respectively.

Virological outcome

The virological outcomes of the 231 patients are shown in Figure 1. Twenty-two (9.5%) patients had confirmed VF with a median HIV RNA concentration of 4.75 log₁₀ copies/mL (IQR: 3.92–5.01 log₁₀ copies/mL). Five of 231 (2.2%) patients had HIV RNA concentrations between 400 and <1000 copies/mL, 4 (1.7%) patients had HIV RNA concentrations between 150 and <400 copies/mL and the remaining 200 (86.6%) patients had undetectable viral loads.

HIV subtypes, antiretroviral resistance mutations and predicted susceptibility of the 22 patients with VF

Of the 22 patients with VF, 21 (95%) were infected with HIV-1 subtype CRF01_AE; a single patient was infected with HIV-1 CRF01_AE/B recombinant. Table 2 shows the mutation profiles

of the 22 patients prior to therapy switch and at VF. The majority of the NRTI and NNRTI resistance mutations detected prior to therapy switch remained detectable at therapy failure, with the NNRTI resistance mutations persisting up to 45 months off NNRTI therapy. Major PI resistance mutations developed in 14 (64%) patients; within this subgroup of patients, the median number of PI resistance mutations was 2 (IQR: 1–3 mutations). The most common PI resistance mutations were V82A/F (64%), M46I/L (57%), I84V (29%) and L76V (21%). Five patients had only one PI resistance mutation; the remaining nine had multiple PI resistance mutations. Minor or accessory PI resistance mutations developed in five patients. Three patients did not have any PI resistance mutations.

Figure 3 shows the predicted resistance profiles of the 22 patients based on their individual genotype profiles. Mutations conferring intermediate- to high-level resistance to the second-line drugs tenofovir disoproxil fumarate, lamivudine and lopinavir/ritonavir were detected in 13 (59%), 18 (82%) and 13 (59%) patients, respectively. Cross-resistance to the second-generation NNRTIs etravirine and rilpivirine was intermediate to high level, and cross-resistance to both was present in 12 (55%) patients. Cross-resistance to the second-generation PIs tipranavir and darunavir was present in 10 (45%) and 6 (27%) patients, respectively. Cross-resistance to darunavir was present only at an intermediate level.

Predictors of second-line virological outcome

Table 3 lists the data for the five covariates entered into the logistic regression model and the results of the univariate and multivariate analyses. The most frequently missing covariates were history of indinavir use (8.7% missing) and viral load (6.9% missing); other covariates were missing in ≤2% of patients. Higher viral load, sub-optimal adherence and previous indinavir use predicted VF in both univariate and multivariate analyses [multivariate ORs: 2.7 (95% CI: 1.1–7.4), *P*=0.039; 7.8 (95% CI: 2.1–31.0), *P*=0.002; and 12.8 (95% CI: 3.7–49.8), *P*<0.001, respectively]. Multivariate analysis shown in Table 3 was based on an analysis excluding missing data.

We performed *ad hoc* univariate and multivariate analyses of factors associated with the development of PI resistance. The three covariates identified to be independent predictors of VF were entered into the logistic regression model. Higher viral load and previous indinavir exposure remained independent predictors of PI resistance in both univariate [ORs: 2.7 (95% CI: 1.1–6.5), *P*=0.03; and 9.7 (95% CI: 3.0–34.2), *P*<0.001, respectively] and multivariate [ORs: 4.3 (95% CI: 1.5–14.8), *P*=0.01; and 13.6 (95% CI: 3.6–61.3), *P*<0.001, respectively] analyses. Adherence did not predict PI resistance in the univariate or multivariate analyses.

Two year follow-up of patients with VF maintained on the failing second-line therapy

The clinical outcomes of the 22 patients with VF are shown in Figure 1 and are also reported along with their treatment history and resistance profiles in Table 2. Seven patients died after a median duration of 8 months (IQR: 8–16 months) from the time of study enrolment: four of tuberculosis and three of severe wasting syndrome. Of the 15 patients who remained alive, two




Figure 2. Prevalence of antiretroviral resistance mutations in 173 patients at the time of switch to second-line therapy in HCMC.

patients were transferred to provincial clinics and declined study follow-up visits. Two patients were switched to raltegravir and darunavir/ritonavir (purchased privately from Thailand for \$600 US/month) and remained on lamivudine. The remaining 11 patients were maintained on the lopinavir/ritonavir-based regimen. Viral load testing was performed at 24 month in the 13 patients in active follow-up. Virological re-suppression was achieved in the two patients who switched to raltegravir and darunavir/ritonavir and in five patients maintained on lopinavir/ritonavir. The CD4 cell counts of the five patients with virological re-suppression on lopinavir/ritonavir increased to a mean of 611 cells/mm³ (range: 384–942 cells/mm³). Of these five patients, two had no major PI resistance mutations and three had only one major mutation—V82A—at VF. The remaining six patients had persistent viral replication (mean HIV RNA concentration: 5.2 log₁₀ copies/mL; range: 4.79–5.70 log₁₀ copies/mL). Table 4 shows the evolution of antiretroviral resistance mutations of these six patients. Patient 18 had no major drug resistance mutations, and the other five had multiple major PI resistance mutations at VF and continued to accumulate NRTI resistance mutations (in five patients) and PI resistance mutations (in two patients). All six patients had worsening immunological control (mean CD4 count: 97 cells/mm³, range: 0–177 cells/mm³); however, there were no AIDS events over the 24 months of follow-up.

Discussion

We report the antiretroviral resistance profiles of patients failing second-line PI-based therapy in Vietnam. The major finding was that amongst the patients experiencing VF, 64% harboured at least one major PI resistance mutation and 60% had mutations that conferred intermediate- to high-level resistance to lopinavir/ritonavir. This level of PI resistance is significantly higher than has been previously reported in either resource-rich or resource-poor settings.^{3,4,8–15,37} Ritonavir-boosted PIs are known to have a high genetic barrier to resistance.^{8,38} The minimum plasma concentrations of ritonavir-boosted PIs far exceed the levels required to inhibit WT virus replication,^{39,40} making PIs a durable class of antiretroviral drug to be used across different patient populations. A high prevalence of PI resistance has been reported in four studies, two of which studied populations from Asia, specifically, from Cambodia (N= 71, 40%)¹⁵ and India (N=45, 73%).¹⁶ The other two study populations were from West Africa: Mali (N=93, 25%)³⁷ and Nigeria (N=61, 62%).⁴¹ Except for the study from India, where indinavir/ritonavir and atazanavir/ritonavir were commonly used, the studies in these other countries used lopinavir/ritonavir for second-line therapy. Previous exposure to generically produced un-boosted indinavir and nelfinavir was implicated in the observed high prevalence of PI resistance mutations in the reports from Asia and Nigeria, although formal analyses were

Table 2. Antiretroviral history, drug resistance profile and 2 year outcomes of 22 patients with VF on second-line ART in HCMC

Patient	Time on second-line ART (months)	At time of therapy switch		Prior PI use	Mutations at time of therapy switch			At time of VF		Mutations at time of VF			Two year outcomes
		CD4 count (cells/mm ³)	viral load (copies/mL)		NRTIs	NNRTIs	PIs	CD4 count (cells/mm ³)	viral load (copies/mL)	NRTIs	NNRTIs	PIs	
1	15	79	4 720 000	no	L74V, M184I	K101E, K103N, G190A, M230L		191	289 000	D67N, K70R, L74V, M184I, K219Q	K101E, K103N, E138G, G190A, M230L	L10I, V82A	virological re-suppression
2	18	2	7 590 000	NA	NA	NA	NA	2	1 630 000	M184V	K103N, V108I, Y181C		death
3	19	13	170 000	IDV	NA	NA	NA	50	402 194	T215S		G16E, K20I, M36I, M46L , I54V, H69K, V82A , L89M	death
4	18	74	118 000	IDV	M41L, D67N, K70R , V75M, M184V, T215F, K219Q	K101P, K103N		303	1574	M41L, D67N, K70R , V75M, M184V, T215F, K219Q	K101P, K103N	L10I, G16E, K20I, M36I, H69K, L89M	transferred to other clinic
5	18	45	435 000	IDV	A62V, K65N , T69S, V75M, F77L, Q151M, M184V	V106I, Y181C, Y188L, H221Y	I54V, N83D , I84R	152	1184	V75M, M184V, T215F	V106I, Y181C, Y188L, H221Y	L10I, K20I, M36I, M46L , F53L, I54V, H69K, V82A , L89I	worsening virological/immunological control
6	29	5	365 000	no	K65R, Q151M	Y181C, G190A	L33F, I84L	143	5490	K65R, Q151M	Y181C, G190A	K20R, L33F, M36I, M46I , I62V, H69K, L76V, I84V , L89M	worsening virological/immunological control
7	6	6	190 000	IDV	A62V, D67N , T69P, V75I, F77L, F116Y, Q151M, M184I, T215S, K219Q	K101E, Y181C, G190A	L10V	293	3910	D67N, V75I, F77L, F116Y, Q151M, M184I, K219Q	K101E, Y181C, G190A	L10V, G16E, M36I, H69K, V82A , L89M	virological re-suppression

Continued

Table 2. Continued

Patient	Time on second-line ART (months)	At time of therapy switch		Prior PI use	Mutations at time of therapy switch			At time of VF		Mutations at time of VF			Two year outcomes
		CD4 count (cells/mm ³)	viral load (copies/mL)		NRTIs	NNRTIs	PIs	CD4 count (cells/mm ³)	viral load (copies/mL)	NRTIs	NNRTIs	PIs	
8	31	40	184 000	no	M41L, D67N, T69N, K70R, L74I, M184V, T215F, K219Q	V108I, G190A	L10IV	546	1520	M41L, D67N, K70R, L74I, M184V, T215F, K219Q	G190A	L10V, G16E, L33F, M36I, I54V, V82A , L89I	virological re-suppression
9	47	8	253 000	IDV	M41L, D67N, T69N, K70R, L74I, M184V, T215F, K219Q	A98G, K103N, G190A		171	37 379	M41L, D67N, K70R, M184V, T215F, K219Q	K103N, G190A	L10V, K20I, L33F, M36L, M46I, I47V, I54V, H69K, T74P, V82F , L89M	worsening virological/immunological control
10	8	21	752 000	NA	NA	NA	NA	152	16 582	K65R , V75M	V179F, Y181C, H221Y	M36I, H69K, L89M	virological re-suppression
11	45	21	867 000	no	M41L, E44AD, D67N, L74V, V75M, V118I, M184V, L210W, T215Y, K219N	A98G, L100I, K101P, G190A		121	96 147	M41L, D67N, V75M, M184V, L210W	A98G, G190A	M36I, H69K, V82I, L89M	death
12	43	1	132 000	no	D67N, K70R, M184V, L210W, T215F, K219W	K103N, V108I, Y181C, G190A		11	22 600	M184V			death
13	50	113	38 238	IDV	M41L, D67N, T69P, K70R, M184V, L210W, T215F, K219E			57	319 798	M41L, D67N, K70R, M184V, L210W, K219QE		L10V, G16E, K20V, L33F, M36I, I47V , I54V, H69K, A71V, I84V , L89M	worsening virological/immunological control
14	12	25	693 000	no	NA	NA	NA	48	875 664			L10I, K20R, M36I, H69K, L89M	virological re-suppression

15	29	211	189000	IDV	T69N, V75M		V32I, M46I, Q58E	253	64262	K70R, V75M, M184V, K219E	V90I	L10I, G16E, K20I, M36I, M46I, Q58E, H69K, K70R, V82A, L89I	worsening virological/immunological control
16	47	44	139000	IDV	M41L, T69N, V75M, F77L, F116Y, Q151M, M184V, T215Y	A98G, L100I, K103N		154	34900	M41L, V75M, F77L, M184V, T215Y	A98G	L10I, G48A, I54V, A71V, V82A	RAL + DRVr + 3TC
17	43	64	174550	IDV	M41L, D67N, K70R, L74V, M184V, T215F, K219Q	Y181C, G190S	M36I	67	47500	M41L, D67N, K70R, L74V, M184V, T215F, K219Q	A98G, Y181C, G190S	L10I, L33F, M46I, I54M, A71V, G73S, I84V	death
18	23	41	377000	no	K65R, V75M	K103N		6	67934			M36I, H69K, V82I, L89M	worsening virological/immunological control
19	17	40	590000	no	D67N, T69N, K70R, L74I, V75M, M184V, T215F, K219E	K101P, Y181C, G190S		352	3776	D67N, K70R, V75M, M184V, T215F, K219E	K101Q, Y181C, G190A	K20R, M36I, M46I, L63P, H69K, A71V, L76V, I84V, L89M	transferred to other clinic
20	30	3	948909	NA	NA	NA	NA	98	103000	K70R, T215F, K219E	A98G, K101E, Y181C, Y188L, G190A	L10I, I54V, N83D	death
21	45	113	2470000	IDV	M41L, D67N, V75M, V118I, M184V, L210W, T215F, K219W	K101P, V108I, G190A	L10F	173	79800	M41L, D67N, V75M, M184V, T215Y	A98G	L10F, M46L, I54V, L76V, V82A, L89V	RAL + DRVr + 3TC
22	26	14	81422	IDV	NA	NA	NA	28	83300	K65R	K101E, Y181C, G190A		death

IDV, indinavir; RAL, raltegravir; DRVr, darunavir/ritonavir; 3TC, lamivudine; NA, not applicable (as data are unknown).
 Bold: major drug resistance mutations according to the IAS-USA 2014.




Figure 3. Predicted antiretroviral susceptibility among 22 patients experiencing VF on second-line ART in HCMC using the Stanford algorithm. AZT, zidovudine; d4T, stavudine; 3TC, lamivudine; FTC, emtricitabine; ABC, abacavir; ddI, didanosine; TDF, tenofovir disoproxil fumarate; EFV, efavirenz; NVP, nevirapine; ETR, etravirine; RPV, rilpivirine; LPVr, lopinavir; IDVr, indinavir; NFV, nelfinavir; ATVr, atazanavir; FPVr, fosamprenavir; SQVr, saquinavir; TPVr, tipranavir; DRVr, darunavir; r, ritonavir-boosted.

Table 3. Factors associated with VF in 231 patients on second-line ART in HCMC

Covariate	Patients without VF (N=209)	Patients with VF (N=22)	Univariate effect		Multivariate effect	
			OR (95% CI)	P	OR (95% CI)	P
CD4 count ^a (by -50 cells/mm^3)	47 (17–88); N=205 ^b	33 (9–59)	1.39 (0.92–2.38)	0.184	1.52 (0.84–3.45)	0.248
HIV RNA concentration ^a (by $+\log_{10} \text{ copies/mL}$)	5.1 (4.6–5.5); N=194 ^b	5.6 (5–5.9); N=21 ^b	3.14 (1.56–6.69)	0.002	2.70 (1.08–7.35)	0.039
Time on failing first-line ART (months)	9 (5–15); N=206 ^b	9 (3–21)	1.01 (0.97–1.05)	0.537	1.01 (0.95–1.07)	0.786
Adherence <95% (yes)	21 (10%)	7 (32%)	4.18 (1.46–11.16)	0.005	7.81 (2.06–31.00)	0.002
Prior indinavir use (yes)	27 (14%); N=192 ^b	9 (47%); N=19 ^b	5.50 (2.02–14.91)	<0.001	12.80 (3.69–49.80)	<0.001

Data are presented as absolute numbers (%) for categorical variables and median (IQR) for continuous variables.

Bold: results with statistical significance.

^aAt time of therapy switch.

^bNumber of patients with complete data on a covariate.

Table 4. Evolution of resistance mutations in six patients with worsening HIV control who were maintained on a failing second-line regimen

Patient	Time on second-line ART (months)	At time of VF		Mutations at time of VF			At 2 year follow-up		Mutations at 2 year follow-up		
		CD4 count (cells/mm ³)	viral load (copies/mL)	NRTIs	NNRTIs	PIs	CD4 count (cells/mm ³)	viral load (copies/mL)	NRTIs	NNRTIs	PIs
5	18	152	1184	V75M, M184V, T215F	V106I, Y181C, Y188L, H221Y	L10I, K20I, M36I, M46L , F53L, I54V, H69K, V82A , L89I	77	93 500	A62V, K65N, V75M, F77L, Q151M, M184V	V106I, Y181C, Y188L, H221Y	L10F, K20I, M36I, M46L , F53L, I54V, H69K, V82A , L89I
6	29	143	5490	K65R, Q151M	Y181C, G190A	K20R, L33F, M36I, M46I , I62V, H69K, L76V, I84V , L89M	177	164 000	K65R, D67N, T69d, Q151M, K219E	Y181C, G190A	L10F, K20R, L33F, M36I, M46I , I62V, H69K, L76V, V82A , T74S, I84V , L89M
9	47	171	37 379	M41L, D67N, K70R, M184V, T215F, K219Q	K103N, G190A	L10V, K20I, L33F, M36L, M46I, I47V , I54V, H69K, T74P, V82F , L89M	159	61 100	M41L, D67N, T69N, K70R, V75M, M184V, L210W, T215F, K219Q	V106I, G190A	L10V, K20I, L33F, M36L, M46I, I47V , I54V, H69K, T74P, V82F , L89M
13	50	57	319 798	M41L, D67N, K70R, M184V, L210W, K219QE		L10V, G16E, K20V, L33F, M36I, I47V , I54V, H69K, A71V, I84V , L89M	10	498 000	M41L, D67N, K70R, M184V, L210W, T215Y , K219D		L10V, G16E, K20V, L33F, M36I, M46I, I47V , I54V, H69K, A71V, G73T, L76M, I84V , L89T
15	29	253	64 262	K70R , V75M, M184V, K219E	V90I	L10I, G16E, K20I, M36I, M46I , I54A, Q58E , H69K, K70R, V82A , L89I	159	97 100	D67H, T69G, K70R , V75M, M184V, T215I, K219E	V90IV	L10I, G16E, K20I, L33F, M36I, M46I , I54A, Q58E , H69K, K70R, V82A , L89I
18	23	6	67 934			M36I, H69K, V82I, L89M	0	279 000		V106I	M36I, H69K, V82I, L89M

Bold: major drug resistance mutations.

lacking. Our study is the first to systematically link previous PI exposure to VF and PI resistance.

Indinavir was generically produced in Vietnam during the early 2000s. The correct dosing was 800 mg three times daily; however, because of the high rate of side effects, many Vietnamese clinicians prescribed it at 400 mg three times daily or 800 mg twice daily. A combination of high pill burden, short half-life, food restriction, high rate of side effects and inadequate dosing likely led to inadequate plasma drug concentrations and increased the risk of PI resistance in patients. Low plasma indinavir concentration has been shown to increase the risk of developing PI resistance mutations in patients experiencing early VF.⁴² Further, the most common PI resistance mutations detected in our cohort—M46I/L, I54V, V82A and L90M—were shown to be the first mutations to be sequentially selected by indinavir therapy.⁴³ Cheap generically made indinavir, nelfinavir and saquinavir were available in India, China and south-east Asian countries during the same time.^{15,44} This availability likely explains the higher prevalence of PI resistance reported in the studies from Cambodia and India and suggests that the scope of PI exposure and resistance in Asia might be larger than is currently appreciated. Another reason for the high level of PI resistance observed in our study as well as these other studies is the lack of viral load monitoring, which leads to late detection of VF and accumulation of PI resistance mutations. Better understanding of the extent and determinants of PI resistance in developing countries is needed.

Among the next-generation NNRTIs and PIs potentially available as third-line drugs, there was evidence of probable intermediate or high levels of cross-resistance to etravirine, rilpivirine and tipranavir in ~50% of patients. Cross-resistance to darunavir was less frequent (27%) and was observed only at the intermediate level. These prevalences are noticeably higher than those found in studies in similar settings.^{15,16,37,41} One reason for the observed high-level etravirine cross-resistance is programmatic. The lack of virological monitoring led to prolonged periods of undetected VF in the presence of the low-genetic-barrier drugs nevirapine and efavirenz and accumulation of resistance mutations. This effect was shown by the extensive NNRTI resistance mutations in our cohort (94% of patients with ≥ 1 and 32% with ≥ 3 major NNRTI resistance mutations). NNRTI resistance mutations have been shown to persist up to 45 months after the discontinuation of NNRTI therapy. This finding is due to the low fitness costs of these mutations on viral replication, thus explaining the slow reversion of these mutant viruses to WT in the absence of drug pressure.^{45,46} The presence of ≥ 3 IAS-USA-defined NNRTI resistance mutations has been associated with decreased virological response to etravirine in the DUET trials.^{47,48}

Another reason for high etravirine cross-resistance is the inherent genetic variability of the HIV-1 subtype CRF01_AE in south-east Asia. Etravirine was designed to work against HIV containing the NNRTI signature mutation—K103N—which is highly prevalent in HIV-1 subtype B.⁴⁹ However the most frequent NNRTI resistance mutations selected in subtype CRF01_AE virus by nevirapine and efavirenz exposure are Y181C and G190A/S, rather than K103N.^{50,51} In the DUET trials, the presence at baseline of these substitutions was associated with impaired virological response to etravirine.^{47,48} High prevalence of cross-resistance to etravirine (60%) has been reported in several studies of CRF01_AE-infected patients in Thailand for whom first-line NNRTI-based therapy was failing.^{52–54} As efficacy data of etravirine use in south-east Asia

are lacking, phenotypic assays investigating the *in vitro* susceptibilities of these clinical isolates would be helpful. Until then, etravirine and rilpivirine should probably be avoided as third-line drugs for patients infected with subtype CRF01_AE in south-east Asia. Our data do not support the 2010 and 2013 WHO recommendations to use etravirine in a third-line ART regimen in resource-limited settings.^{1,25} The phenotypic susceptibility of tipranavir is not as well predicted as that of darunavir by most genotypic interpretation algorithms, in particular for non-B subtypes.⁵⁵ However, based on our predicted cross-resistance data, darunavir/ritonavir plus a brand-new class of antiretroviral drug, such as integrase strand transfer inhibitors (INSTIs), combined with lamivudine is a reasonable third-line option for Vietnam. As the need for third-line therapy is imminent in the developing world, clinical trials evaluating cost-effective third-line treatment strategies and regimens are needed.

Among the 20 patients who were maintained on the failing lopinavir/ritonavir regimen, death or worse virological/immunological control occurred for 13 patients, with accumulation of resistance mutations occurring in those who remained alive at 24 months. This finding is consistent with that of a study from Nigeria showing accumulation of PI resistance mutations in patients maintained on failing second-line therapy.⁴¹ However, virological re-suppression and good immune response were achieved in five patients; these patients either had no or only one major PI resistance mutation at VF detection. A strategy combining adherence intervention and close monitoring of patients failing second-line therapy before switching to third-line therapy would be cost saving yet effective in resource-poor settings.

Our study has limitations. The study captured VF at one point in time and only in patients who were in active follow-up. The unavoidable exclusion of the 12% who had died and the 14% who had been transferred to their respective resident provinces reduces the power of our observations. Further, PI resistance might be underestimated due to the lack of data from those who had died. Nevertheless, the study site is the largest centre for second-line therapy in Vietnam. The highly uniform HIV care system along with standardized ART regimens in the national programme allow for reasonable generalizability of our findings. We did not sequence the integrase gene in this cohort, as INSTIs are not yet available in Vietnam.

In conclusion, we identified a significantly higher prevalence of PI resistance in patients failing second-line therapy in Vietnam, which was associated with previous indinavir exposure. The widespread availability of generically made PIs in Asia suggests that the scope of PI resistance might be underestimated in this region. Our data emphasize the need for viral load monitoring to limit the accumulation of NRTI and NNRTI resistance mutations, thus improving second-line treatment outcome and preserving the limited third-line therapy options. Significant cross-resistance to etravirine is common in subtype CRF01_AE-infected patients failing NNRTI therapy, suggesting that etravirine should be avoided as a third-line therapy drug. Research on cost-effective strategies and timing of third-line therapy switch are now needed.

Acknowledgements

We would like to thank the patients for their participation in the study and thank the staff in the HIV Outpatient Clinic at the Hospital for Tropical Diseases for their assistance with the enrolment of patients.

Funding

This work was supported by the Wellcome Trust.

Transparency declarations

None to declare.

Author contributions

Study concept and design: T. L., V. M. Q., C. S., S. D. and J. F. Obtaining funding: T. L., S. D., J. D. and J. F. Acquisition of data: V. P. T., V. M. Q., N. T. C., N. V. V. C. and T. L. Analysis and interpretation of the data: V. P. T. and T. L. Drafting the manuscript: V. P. T. and T. L. Critical revision of the manuscript for important intellectual content: V. M. Q., N. T. C., C. S., J. F., J. D., N. V. V. C., S. D. and G. T. All authors contributed to and approved the final manuscript.

References

- 1 WHO. *Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection*. 2013. http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf.
- 2 Murphy RL, da Silva B a, Hicks CB *et al*. Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naïve HIV-1-infected patients. *HIV Clin Trials* 2008; **9**: 1–10.
- 3 Eron JJ, Yeni P, Gathe JJ *et al*. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. *Lancet* 2006; **368**: 476–82.
- 4 Riddler SA, Haubrich R, DiRienzo AG *et al*. Class-sparing regimens for initial treatment of HIV-1 infection. *N Engl J Med* 2008; **358**: 2095–106.
- 5 Pujades-Rodríguez M, Balkan S, Arnould L *et al*. Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries. *JAMA* 2010; **304**: 303–12.
- 6 AJose O, Mookerjee S, Mills EJ *et al*. Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis. *AIDS* 2012; **26**: 929–38.
- 7 Ortiz R, Dejesus E, Khanlou H *et al*. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naïve HIV-1-infected patients at week 48. *AIDS* 2008; **22**: 1389–97.
- 8 Kempf DJ, King MS, Bernstein B *et al*. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. *J Infect Dis* 2004; **189**: 51–60.
- 9 Daar ES, Tierney C, Fischl MA *et al*. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1: a randomized trial. *Ann Intern Med* 2012; **154**: 445–56.
- 10 Levison JH, Orrell C, Gallien S *et al*. Virologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South Africa. *PLoS One* 2012; **7**: e32144.
- 11 El-khatib Z, Ekström AM, Ledwaba J *et al*. Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. *AIDS* 2010; **24**: 1679–87.
- 12 Wallis CL, Mellors JW, Venter WDF *et al*. Protease inhibitor resistance is uncommon in HIV-1 subtype C infected patients on failing second-line lopinavir/r-containing antiretroviral therapy in South Africa. *AIDS Res Treat* 2011; **2011**: 769627.
- 13 Van Zyl GU, Van Mens TE, McIlleron H *et al*. Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting. *J Acquir Immune Defic Syndr* 2011; **56**: 333–9.
- 14 Reynolds SJ, Laeyendecker O, Nakigozi G *et al*. Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda. *AIDS Res Hum Retroviruses* 2012; **28**: 1739–44.
- 15 Nerrienet E, Nouhin J, Ngin S *et al*. HIV-1 protease inhibitors resistance profiles in patients with virological failure on LPV/r-based 2nd line regimen in Cambodia. *J AIDS Clin Res* 2012; **55**: 003.
- 16 Saravanan S, Vidya M, Balakrishnan P *et al*. Viremia and HIV-1 drug resistance mutations among patients receiving second-line highly active antiretroviral therapy in Chennai, Southern India. *Clin Infect Dis* 2012; **54**: 995–1000.
- 17 Lan NTH, Recordon-Pinson P, Hung PV *et al*. HIV type 1 isolates from 200 untreated individuals in Ho Chi Minh City (Vietnam): ANRS 1257 Study. Large predominance of CRF01_AE and presence of major resistance mutations to antiretroviral drugs. *AIDS Res Hum Retroviruses* 2003; **19**: 925–8.
- 18 Thao VP, Le T, Török ME *et al*. HIV-1 drug resistance in antiretroviral-naïve individuals with HIV-associated tuberculous meningitis initiating antiretroviral therapy in Vietnam. *Antivir Ther* 2012; **17**: 905–13.
- 19 Ayoub A, Lien TTX, Nouhin J *et al*. Low prevalence of HIV type 1 drug resistance mutations in untreated, recently infected patients from Burkina Faso, Côte d'Ivoire, Senegal, Thailand, and Vietnam: the ANRS 12134 study. *AIDS Res Hum Retroviruses* 2009; **25**: 1193–6.
- 20 Ishizaki A, Cuong NH, Thuc PV *et al*. Profile of HIV type 1 infection and genotypic resistance mutations to antiretroviral drugs in treatment-naïve HIV type 1-infected individuals in Hai Phong, Viet Nam. *AIDS Res Hum Retroviruses* 2009; **25**: 175–82.
- 21 Phan TTC, Ishizaki A, Phung DC *et al*. Characterization of HIV type 1 genotypes and drug resistance mutations among drug-naïve HIV type 1-infected patients in Northern Vietnam. *AIDS Res Hum Retroviruses* 2010; **26**: 233–5.
- 22 UNAIDS. *HIV in Asia and the Pacific*. 2013. http://www.unaids.org/sites/default/files/media_asset/2013_HIV-Asia-Pacific_en_0.pdf.
- 23 Vietnam Ministry of Health. *HIV/AIDS Case Report and Implementation of HIV/AIDS Prevention and Control Programme Till September 2014*. 2014. <http://www.bacsisaigon.com/tin-tuc/tinh-hinh-dich-hiv-aids-o-viet-nam-den-het-30-9-2014-va-ket-qua-mot-so-chuong-trinh/>.
- 24 Chi NH, Quang VM, Chinh NT. Antiretroviral therapy in HIV/AIDS patients and the resistance of ARVs. In: *Workshop on HIV/AIDS in Vietnam—Organized by Hospital for Tropical Diseases and Harvard Medical School AIDS Initiative in Vietnam*. 2012.
- 25 WHO. *Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach: 2010 Revision*. 2010. http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf.
- 26 Vietnam Ministry of Health. *Vietnam National Guidelines for HIV/AIDS Diagnosis and Treatment*. In Vietnamese. Published with the Decision No. 3003/QĐ-BYT dated 19/08/2009 of the Minister of Health. 2011. http://www.vaac.gov.vn/Cms_Data/Contents/Vaac/Folders/DocumentLaw/Vanban/~contents/8YUJW54X7VRF64XS/4139-Q-BYT.pdf.
- 27 Vietnam Ministry of Health. *Vietnam National Guidelines for HIV/AIDS Diagnosis and Treatment*. In Vietnamese. Published with the Decision No. 06/2005/QĐ-BYT dated 07/03/2005 of the Minister of Health. 2005. http://moj.gov.vn/vbpq/Lists/Vn%20bn%20php%20lut/View_Detail.aspx?ItemID=15388.
- 28 Vietnam Ministry of Health. *Vietnam National Guidelines for HIV/AIDS Diagnosis and Treatment*. In Vietnamese. 2009. http://benhnhietdoi.vn/data/files/documents/QD.3003.BYT.19.8.2009_Huong_dan_chan_doan_va_dieu_tri_HIVAIDS.pdf.
- 29 Kalichman S, Amaral C, Swetzes C *et al*. A simple single item rating scale to measure medication adherence: further evidence for convergent validity. *J Int Assoc Physicians AIDS Care* 2011; **8**: 367–74.

- 30 Wensing AM, Calvez V, Günthard HF et al. 2014 update of the drug resistance mutations in HIV-1. *Top Antivir Med* 2014; **22**: 642–50.
- 31 Pineda-Peña A-C, Faria NR, Imbrechts S et al. Automated subtyping of HIV-1 genetic sequences for clinical and surveillance purposes: performance evaluation of the new REGA version 3 and seven other tools. *Infect Genet Evol* 2013; **19**: 337–48.
- 32 Win MM, Maek-A-Nantawat W, Phonrat B et al. Virologic and immunologic outcomes of the second-line regimens of antiretroviral therapy among HIV-infected patients in Thailand. *J Int Assoc Physicians AIDS Care* 2011; **10**: 57–63.
- 33 Fox MP, Ive P, Long L et al. High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa. *J Acquir Immune Defic Syndr* 2010; **53**: 500–6.
- 34 Hosseinipour MC, Kumwenda JJ, Weigel R et al. Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline. *HIV Med* 2010; **11**: 510–8.
- 35 Levison JH, Orrell C, Losina E et al. Early outcomes and the virologic impact of delayed treatment switching on second-line therapy in an antiretroviral roll-out program in South Africa. *Antivir Ther* 2011; **16**: 853–61.
- 36 Sigaloff KCE, Hamers RL, Wallis CL et al. Second-line antiretroviral treatment successfully resuppresses drug-resistant HIV-1 after first-line failure: prospective cohort in sub-Saharan Africa. *J Infect Dis* 2012; **205**: 1739–44.
- 37 Maiga AI, Fofana DBD, Cisse M et al. Characterization of HIV-1 antiretroviral drug resistance after second-line treatment failure in Mali, a limited-resources setting. *J Antimicrob Chemother* 2012; **67**: 2943–8.
- 38 Tang MW, Shafer RW. HIV-1 antiretroviral resistance scientific principles and clinical applications. *Drugs* 2012; **72**: e1–25.
- 39 Hoetelmans R. Pharmacological exposure and the development of drug resistance in HIV. *Antiretrovir Ther* 2001; **6**: 37–47.
- 40 Zeldin RK. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. *J Antimicrob Chemother* 2003; **53**: 4–9.
- 41 Rawizza HE, Chaplin B, Meloni ST et al. Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria. *PLoS One* 2013; **8**: e73582.
- 42 González de Requena D, Gallego O, de Mendoza C et al. Indinavir plasma concentrations and resistance mutations in patients experiencing early virological failure. *AIDS Res Hum Retroviruses* 2003; **19**: 457–9.
- 43 Zhang Y, Imamichi H, Imamichi T et al. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. *J Virol* 1997; **71**: 6662–70.
- 44 Boettiger DC, Kerr S, Ditangco R et al. Trends in first-line antiretroviral therapy in Asia: results from the TREAT Asia HIV observational database. *PLoS One* 2014; **9**: e106525.
- 45 Arts EJ, Hazuda DJ. HIV-1 antiretroviral drug therapy. *Cold Spring Harb Perspect Med* 2012; **2**: a007161.
- 46 Jain V, Sucupira MC, Bacchetti P et al. Differential persistence of transmitted HIV-1 drug resistance mutation classes. *J Infect Dis* 2011; **203**: 1174–81.
- 47 Tambuyzer L, Vingerhoets J, Azijn H et al. Characterization of genotypic and phenotypic changes in HIV-1-infected patients with virologic failure on an efavirenz-containing regimen in the DUET-1 and DUET-2 clinical studies. *AIDS Res Hum Retroviruses* 2010; **26**: 1197–205.
- 48 Vingerhoets J, Tambuyzer L, Azijn H et al. Resistance profile of efavirenz: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies. *AIDS* 2010; **24**: 503–14.
- 49 Andries K, Azijn H, Thielemans T et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. *Antimicrob Agents Chemother* 2004; **48**: 4680–6.
- 50 Zolfo M, Schapiro JM, Phan V et al. Genotypic impact of prolonged detectable HIV type 1 RNA viral load after HAART failure in a CRF01_AE-infected cohort. *AIDS Res Hum Retroviruses* 2011; **27**: 727–35.
- 51 Chetchotisakd P, Anunnatsiri S, Kiertiburanakul S et al. High rate multiple drug resistances in HIV-infected patients failing nonnucleoside reverse transcriptase inhibitor regimens in Thailand, where subtype A/E is predominant. *J Int Assoc Physicians AIDS Care* 2006; **5**: 152–6.
- 52 Teeranaipong P, Sirivichayakul S, Mekprasan S et al. Rilpivirine versus efavirenz validity in NNRTI-based treatment failure in Thailand. *J Int AIDS Soc* 2014; **17**: 19740.
- 53 Manosuthi W, Butler D, Chantratita W et al. Patients infected with HIV type 1 subtype CRF01_AE and failing first-line nevirapine- and efavirenz-based regimens demonstrate considerable cross-resistance to efavirenz. *AIDS Res Hum Retroviruses* 2010; **26**: 609–11.
- 54 Bunupuradah T, Ananworanich J, Chetchotisakd P et al. Efavirenz and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens. *Antivir Ther* 2011; **16**: 1113–21.
- 55 Talbot A, Grant P, Taylor J et al. Predicting tipranavir and darunavir resistance using genotypic, phenotypic, and virtual phenotypic resistance patterns: an independent cohort analysis of clinical isolates highly resistant to all other protease inhibitors. *Antimicrob Agents Chemother* 2010; **54**: 2473–9.